The Effect of CoQ 10 Supplementation on Quality of Life in Women with Breast Cancer Undergoing Tamoxifen Therapy: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Autor: Hosseini SA; Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Zahrooni N; Department of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Ahmadzadeh A; Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Ahmadiangali K; Biostatistics Division, Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Assarehzadegan MA; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Science, Tehran, Iran.
Jazyk: angličtina
Zdroj: Psychology research and behavior management [Psychol Res Behav Manag] 2020 Feb 20; Vol. 13, pp. 151-159. Date of Electronic Publication: 2020 Feb 20 (Print Publication: 2020).
DOI: 10.2147/PRBM.S241431
Abstrakt: Background: Survival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life (QOL). The objective of this study was to determine the efficacy of CoQ 10 on QOL scores among breast cancer patients in Iranian undergoing tamoxifen therapy.
Methods: Thirty breast cancer patients were randomized into two groups. The first group received 100 mg CoQ 10 , and the second group took fplacebo once a day for 8 weeks. QOL was evaluated by a standard QOL questionnaire and a specific questionnaire on QOL of breast cancer patients at baseline and the end of the study. Also, physical activity of patients was assessed with the IPAQ questionnaire and dietary intake determined by a 3-day dietary record.
Results: The data of 30 subjects were analyzed. According to QOL C30 data, CoQ 10 led to a significant increase in physical functioning ( P =0.029), emotional functioning ( P =0.031), and cognitive functioning ( P =0.023) compared to placebo. Symptom scales revealed a notable reduction in appetite loss in the first group ( P =0.01). Global health status showed no significant changes in either study arm. On the QOL BR23, progress in functions and decline in symptoms were not statistically significant. Arm symptoms showed significant reduction ( P =0.022) in patients that received placebo.
Conclusion: This trial indicates that CoQ 10 supplementation has effects in ameliorating some dimensions of QOL in breast cancer patients. To generalize the results, larger and longer intervention studies are needed.
Clinical Trial Registration: IRCT2015042021874N1.
Competing Interests: The authors report no conflicts of interest in this work.
(© 2020 Hosseini et al.)
Databáze: MEDLINE
Externí odkaz: